AgomAb Therapeutics NV American Depositary Shares (AGMB)

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.01, providing financial flexibility
• Altman Z-Score of 16.1 confirms minimal bankruptcy risk and strong solvency

Concerns

• Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

AgomAb Therapeutics NV American Depositary Shares is a micro-cap healthcare company valued at $518 million. From a quality standpoint, AgomAb shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and Altman Z-Score of 16.1 confirms fortress-level solvency. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer